A clear pattern is emerging in US technology funding: investors are placing large bets on startups that aim to scan the human body for early signs of disease. Spotify founder Daniel Ek's Neko Health raised $700 million to build a business around body scanning, and it is not alone. Midjourney is building its own body scanner, while Function Health has also raised significant capital for its preventative-health platform, as TechCrunch reported. The common thread is that investors see preventative healthcare as a scalable, consumer-facing category rather than a niche clinical service.
The size of the bet
Neko Health's $700 million raise is the most visible signal. That is a substantial sum for a company selling a scanning service, and it suggests investors are underwriting a future in which healthy adults routinely pay for advanced imaging and biomarker analysis. The fact that Neko Health is expanding to America matters because the US market is where consumer health spending is largest and where reimbursement and regulatory pathways are most complex. A $700 million raise is not a small pilot; it is a bet that the category can support a large standalone company. As TechCrunch noted, the investor behind that round is betting on scanning your whole body.
A category, not a company
What makes this a funding trend rather than a single story is the presence of multiple players. Midjourney, known for generative image software, is building its own body scanner. Function Health has raised significant capital to build out a preventative-health platform. These are different starting points, one from consumer AI, one from health diagnostics, but they are converging on the same thesis. Investors are funding a category because they expect demand for preventative scanning and monitoring to grow beyond early adopters. When multiple well-capitalized entrants appear at once, it usually means the venture community believes the market is large enough to support several winners.
Why investors are betting on scanning
The appeal is structural. Preventative health promises to shift spending from expensive late-stage treatment to earlier, cheaper detection. For investors, that translates into recurring revenue if customers scan annually and subscribe to monitoring. Body scanning also generates data, which can be used to improve algorithms and personalize recommendations, creating a defensible moat. The US healthcare system has long rewarded treatment over prevention, but consumers increasingly pay out of pocket for wellness and diagnostics. That direct-pay model avoids the slow reimbursement cycle and lets startups scale faster. The result is a funding environment where a $700 million round for a scanning company can be justified as a category-defining bet.
What it means for US technology companies
The influx of capital into preventative health scanning has implications for US technology companies beyond healthcare. It signals that investors are willing to fund hardware-heavy, regulated businesses if the consumer value proposition is clear. For US tech firms, this could pull talent and capital toward health-adjacent hardware and data platforms. It also raises the competitive bar for digital health startups that previously focused on software-only solutions. Companies that can combine imaging, sensors, and software into a seamless consumer experience may find it easier to raise large rounds. Those that cannot may struggle to differentiate as the category matures.
